167 related articles for article (PubMed ID: 29982740)
1. Copy number profiling across glioblastoma populations has implications for clinical trial design.
Cimino PJ; McFerrin L; Wirsching HG; Arora S; Bolouri H; Rabadan R; Weller M; Holland EC
Neuro Oncol; 2018 Sep; 20(10):1368-1373. PubMed ID: 29982740
[TBL] [Abstract][Full Text] [Related]
2. Glioblastoma Multiforme: Fewer Tumor Copy Number Segments of the
Lehrer S; Rheinstein PH; Rosenzweig KE
Cancer Genomics Proteomics; 2018; 15(4):273-278. PubMed ID: 29976632
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive genetic alteration profiling in primary and recurrent glioblastoma.
Neilsen BK; Sleightholm R; McComb R; Ramkissoon SH; Ross JS; Corona RJ; Miller VA; Cooke M; Aizenberg MR
J Neurooncol; 2019 Mar; 142(1):111-118. PubMed ID: 30535594
[TBL] [Abstract][Full Text] [Related]
4. A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications.
Gobin M; Nazarov PV; Warta R; Timmer M; Reifenberger G; Felsberg J; Vallar L; Chalmers AJ; Herold-Mende CC; Goldbrunner R; Niclou SP; Van Dyck E
Cancer Res; 2019 Mar; 79(6):1226-1238. PubMed ID: 30674534
[TBL] [Abstract][Full Text] [Related]
5. Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis.
Kim YW; Koul D; Kim SH; Lucio-Eterovic AK; Freire PR; Yao J; Wang J; Almeida JS; Aldape K; Yung WK
Neuro Oncol; 2013 Jul; 15(7):829-39. PubMed ID: 23502430
[TBL] [Abstract][Full Text] [Related]
6. Distribution differences in prognostic copy number alteration profiles in IDH-wild-type glioblastoma cause survival discrepancies across cohorts.
Umehara T; Arita H; Yoshioka E; Shofuda T; Kanematsu D; Kinoshita M; Kodama Y; Mano M; Kagawa N; Fujimoto Y; Okita Y; Nonaka M; Nakajo K; Uda T; Tsuyuguchi N; Fukai J; Fujita K; Sakamoto D; Mori K; Kishima H; Kanemura Y
Acta Neuropathol Commun; 2019 Jun; 7(1):99. PubMed ID: 31215469
[TBL] [Abstract][Full Text] [Related]
7. Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.
Cimino PJ; Zager M; McFerrin L; Wirsching HG; Bolouri H; Hentschel B; von Deimling A; Jones D; Reifenberger G; Weller M; Holland EC
Acta Neuropathol Commun; 2017 May; 5(1):39. PubMed ID: 28532485
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.
Li R; Chen X; You Y; Wang X; Liu Y; Hu Q; Yan W
Oncotarget; 2015 Oct; 6(31):30968-74. PubMed ID: 26427041
[TBL] [Abstract][Full Text] [Related]
9. Survival kinase genes present prognostic significance in glioblastoma.
Varghese RT; Liang Y; Guan T; Franck CT; Kelly DF; Sheng Z
Oncotarget; 2016 Apr; 7(15):20140-51. PubMed ID: 26956052
[TBL] [Abstract][Full Text] [Related]
10. Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio.
Nowosielski M; Ellingson BM; Chinot OL; Garcia J; Revil C; Radbruch A; Nishikawa R; Mason WP; Henriksson R; Saran F; Kickingereder P; Platten M; Sandmann T; Abrey LE; Cloughesy TF; Bendszus M; Wick W
Neuro Oncol; 2018 Mar; 20(4):557-566. PubMed ID: 29016943
[TBL] [Abstract][Full Text] [Related]
11. Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors.
Rosenberg S; Verreault M; Schmitt C; Guegan J; Guehennec J; Levasseur C; Marie Y; Bielle F; Mokhtari K; Hoang-Xuan K; Ligon K; Sanson M; Delattre JY; Idbaih A
Neuro Oncol; 2017 Feb; 19(2):219-228. PubMed ID: 27571888
[TBL] [Abstract][Full Text] [Related]
12. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
13. GSVD comparison of patient-matched normal and tumor aCGH profiles reveals global copy-number alterations predicting glioblastoma multiforme survival.
Lee CH; Alpert BO; Sankaranarayanan P; Alter O
PLoS One; 2012; 7(1):e30098. PubMed ID: 22291905
[TBL] [Abstract][Full Text] [Related]
14. Molecular subtypes of glioma identified by genome-wide methylation profiling.
Kloosterhof NK; de Rooi JJ; Kros M; Eilers PH; Sillevis Smitt PA; van den Bent MJ; French PJ
Genes Chromosomes Cancer; 2013 Jul; 52(7):665-74. PubMed ID: 23629961
[TBL] [Abstract][Full Text] [Related]
15. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
[TBL] [Abstract][Full Text] [Related]
16. Integrated analysis of 34 microarray datasets reveals CBX3 as a diagnostic and prognostic biomarker in glioblastoma.
Wang S; Liu F; Wang Y; Fan W; Zhao H; Liu L; Cen C; Jiang X; Sun M; Han P
J Transl Med; 2019 May; 17(1):179. PubMed ID: 31138312
[TBL] [Abstract][Full Text] [Related]
17. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
18. Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.
Erdem-Eraslan L; van den Bent MJ; Hoogstrate Y; Naz-Khan H; Stubbs A; van der Spek P; Böttcher R; Gao Y; de Wit M; Taal W; Oosterkamp HM; Walenkamp A; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; van der Holt B; Vernhout RM; Sillevis Smitt PA; Kros JM; French PJ
Cancer Res; 2016 Feb; 76(3):525-34. PubMed ID: 26762204
[TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
Aoki K; Nakamura H; Suzuki H; Matsuo K; Kataoka K; Shimamura T; Motomura K; Ohka F; Shiina S; Yamamoto T; Nagata Y; Yoshizato T; Mizoguchi M; Abe T; Momii Y; Muragaki Y; Watanabe R; Ito I; Sanada M; Yajima H; Morita N; Takeuchi I; Miyano S; Wakabayashi T; Ogawa S; Natsume A
Neuro Oncol; 2018 Jan; 20(1):66-77. PubMed ID: 29016839
[TBL] [Abstract][Full Text] [Related]
20. Genomic copy number variation correlates with survival outcomes in WHO grade IV glioma.
Buchwald ZS; Tian S; Rossi M; Smith GH; Switchenko J; Hauenstein JE; Moreno CS; Press RH; Prabhu RS; Zhong J; Saxe DF; Neill SG; Olson JJ; Crocker IR; Curran WJ; Shu HG
Sci Rep; 2020 Apr; 10(1):7355. PubMed ID: 32355162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
